Proteome Sciences plc (PRM) Ordinary 1p
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Proteome Sciences gives bullish outlook for 2025
23 December 2024 11:56
(Sharecast News) - Shares in drug development services group Proteome Sciences rose on Monday after the company said 2024 results should reflect a good recovery and that its pipeline is looking strong for...
-
Proteome Sciences swings to EBITDA loss, CEO steps down
13 September 2024 12:02
(Sharecast News) - Proteome Sciences announced a significant drop in first-half revenue and profit on Friday, alongside the departure of its chief executive.
-
Proteome Sciences secures contract win with US biopharmaceutical firm
26 April 2024 09:45
(Sharecast News) - Contract proteomics service Proteome Sciences has secured a contract win from a US biopharmaceutical company using the company's mass spectrometry services for the analysis of samples...
-
Proteome launches San Diego lab operations
2 January 2024 14:44
(Sharecast News) - Proteomics services provider Proteome Sciences announced the installation and start of operations at its new laboratory in San Diego, California, on Tuesday.
-
Proteome Sciences issues profit warning after project delays
1 December 2023 12:01
(Sharecast News) - Proteome Sciences, the AIM-listed protein sequencing contract research organisation, has warned it will swing to a net loss this year with full-year sales lower than expected.
-
Proteome Sciences revenue, earnings dip in firist half
25 August 2023 09:11
(Sharecast News) - Proteome Sciences released its unaudited financial results for the first six months of the year on Friday, reporting an increase in its proteomics services revenues to £1.01m, from...
-
Proteome Sciences to open new San Diego facility
12 May 2023 11:07
(Sharecast News) - Proteomics service provider Proteome Sciences announced its plan to expand operations into the United States on Friday, with a new facility to be located in San Diego, California.
-
Proteome Sciences reports solid growth in 2022
4 April 2023 11:44
(Sharecast News) - Biotechnology company Proteome Sciences reported total revenues of £7.78m in its final results on Tuesday - a significant year-on-year increase from £5.13m.
-
Proteome FY revenues rise, operating costs increase
20 February 2023 11:33
(Sharecast News) - Shares in contract proteomics services provider Proteome said on Monday that it now expects full-year operating costs to have risen amid, offsetting revenue growth amid an increased...
-
Proteome gets milestone payment from Thermo Scientific
5 January 2023 16:31
(Sharecast News) - Proteome Group announced a milestone payment for sales of 'TMT' and 'TMTpro' on Thursday.
-
Proteome reaches milestone in launch of proteomics service
3 August 2022 15:33
(Sharecast News) - Proteome Sciences has completed its next milestone towards the launch of 'single cell proteomics' services, it announced on Wednesday, dubbed 'SysQuant SCP'.
-
Proteome Sciences maintains strong order book
16 May 2022 13:35
(Sharecast News) - Proteome Sciences said in an update on Monday that it had maintained a strong order book after recording a small profit in 2021.
Company announcements Announcements
-
Loan Facility, Trading Update & Directorate Change
23 December 2024 07:08
Proteome Sciences
-
Interim Results and Directorate Change
13 September 2024 07:00
Proteome Sciences
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.